Clarithromycin Tablets Market Report 2024

This Clarithromycin Tablets market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The clarithromycin tablets market size has grown strongly in recent years. It will grow from $1.91 billion in 2023 to $2.09 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historical period can be attributed to the increasing global burden of infections, a rise in Helicobacter pylori infections, the growing production of generic medications, a higher incidence of respiratory diseases, and the expansion of skin and bacterial infections.

The clarithromycin tablets market size is expected to see strong growth in the next few years. It will grow to $2.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth projected for the forecast period can be attributed to the increase in gastrointestinal infections, the expanding use of clarithromycin in combination therapies, improved access to healthcare in emerging economies, the rise in antibiotic resistance, and the growing adoption of pulmonary medicines. Key trends during this period include the development of new clarithromycin formulations and combinations, the introduction of generic versions, research into clarithromycin-based therapies, advancements in manufacturing technologies, and innovations in drug formulations.

The increasing prevalence of respiratory infections is anticipated to drive the growth of the clarithromycin tablet market in the coming years. Respiratory infections, which affect the airways, lungs, and other breathing structures, can be caused by viruses, bacteria, or fungi and can range in severity from mild to severe. Factors such as rising air pollution, climate change, and the spread of pathogens in densely populated areas contribute to the growing number of respiratory infections. Clarithromycin tablets are an effective treatment option for these infections, as they target a broad spectrum of bacteria and offer potent antibiotic relief. For example, the National Health Service in the UK reported a 149% increase in hospital admissions for children with asthma in England and Wales between 2021 and 2022. Similarly, the Australian Bureau of Statistics noted that approximately 2.8 million Australians (10.8% of the population) had asthma in 2022. These trends highlight how the rising prevalence of respiratory infections is fueling demand for clarithromycin tablets.

Leading companies in the clarithromycin tablet market are focusing on innovative developments, such as Vonoprazan Tablets, to treat Helicobacter pylori (H. pylori) infections. These innovations aim to improve eradication rates, enhance patient compliance, and combat the growing issue of antibiotic resistance. Vonoprazan tablets, which reduce stomach acid, are used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. In October 2023, Phathom Pharmaceuticals, a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for the reformulation of vonoprazan tablets, including VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. These regimens are designed to treat H. pylori infections in adults, with the TRIPLE PAK containing vonoprazan tablets, amoxicillin capsules, and clarithromycin tablets, and the DUAL PAK including vonoprazan tablets and amoxicillin capsules. The reformulation of vonoprazan, a potassium-competitive acid blocker (PCAB), introduces a new class of acid suppressants to the market.

In June 2024, Lotus Pharmaceuticals Co. Ltd., a Taiwan-based company, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed sum. This acquisition is expected to boost Lotus Pharmaceuticals' growth, broaden its product portfolio, and extend its global reach. Teva Pharmaceutical Industries Ltd., based in Israel, is a manufacturer of clarithromycin tablets.

Major companies operating in the clarithromycin tablets market are AbbVie Inc., Bayer AG, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Cipla Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Medochemie Ltd., Takeda Pharmaceutical Company Ltd., Strides Pharma Science Ltd., LGM Pharma LLC, Envee Drugs Pvt. Ltd., SM Biomed Sdn Bhd, Wockhardt Ltd.

North America was the largest region in the clarithromycin tablets market in 2023. The regions covered in the clarithromycin tablets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clarithromycin tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Clarithromycin tablets are oral antibiotics designed to treat a range of bacterial infections. They function by inhibiting the synthesis of proteins in bacteria. By binding to the bacterial ribosome, they obstruct the creation of proteins necessary for bacterial growth and reproduction, thus assisting in eliminating the infection.

The primarily types of clarithromycin tablets such as 250 mg and 500 mg. The 250 mg tablets contain 250 milligrams of clarithromycin, which is utilized to address bacterial infections. These tablets are available through multiple distribution channels, including hospital pharmacies, online pharmacies, retail pharmacies, and clinics. They are applied in various medical fields, such as dermatology, ENT (ear, nose, and throat), thoracic and cardiovascular medicine, pediatric care, and pulmonary medicine.

The clarithromycin tablets market research report is one of a series of new reports that provides clarithromycin tablets market statistics, including clarithromycin tablets industry global market size, regional shares, competitors with a clarithromycin tablets market share, detailed clarithromycin tablets market segments, market trends, and opportunities, and any further data you may need to thrive in the clarithromycin tablets industry. This clarithromycin tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clarithromycin tablets market consists of sales of extended-release tablets, and immediate-release tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.